美年健康广州城市群总经理刘辉指出，合作将重点聚焦三方面内容：一是建立绿色转诊通道，为体检中发现异常指标的客户提供快速就医服务；二是推进专 家资源共享，邀请市一医院专家参与美年健康的医疗质量控制和疑难病例会诊；三是共同开发覆盖全流程的健康管理方案，推动预防医学与临床医疗的有效 融合。 根据协议，广州市第一人民医院将与美年健康旗下位于越秀、天河、花都等区域的4家体检中心建立首批合作。这一布局旨在覆盖人口密集、健康需求较为 集中的区域，延伸公立医院服务半径，提升区域健康服务整体效率。 广州市第一人民医院应逸副院长在致辞中表示，医院作为具有百年历史的卫生部首批三级甲等医院和广东省高水平医院建设单位，拥有4个国家临床重点专 科和21个省临床重点专科。与美年健康这类规模化、标准化的健康体检机构合作，有助于实现医疗资源的优化配置与服务互补。此次合作将推行"就医五优 先"机制，设立专人响应流程，强化转诊衔接，为市民提供更加高效、连贯的健康服务。 9月15日下午，广州市第一人民医院与美年健康广州城市群医联体签约仪式暨智慧中医报告发布会在广州美年健康天河东分院举行。双方将围绕"筛查—诊断 —治疗—康复"全流程健康服务展开合作，共 ...

Group 1 - The study indicates that for low-risk acute ischemic stroke (AIS) patients, reducing the traditional monitoring frequency from 37 to 17 times within 24 hours is both safe and effective, optimizing medical resource allocation [1][3] - The research involved a collaboration among teams from Fudan University, Johns Hopkins University, and other institutions, covering 4,922 patients across 114 hospitals in 8 countries [1][2] - The findings were published in The Lancet, highlighting the results of the OPTIMISTmain trial, which focuses on monitoring frequency after venous thrombolysis for brain infarction [1][2] Group 2 - Acute stroke is the second leading cause of death and the third leading cause of disability globally, making stroke prevention and treatment a public health priority [2] - The traditional monitoring protocol, established in the 1990s, is resource-intensive and can interfere with patient rest and nursing staff's ability to provide education and support [2][3] - The study found no significant differences in key outcomes such as 90-day poor prognosis, incidence of brain hemorrhage, and serious adverse events between the two monitoring groups [3] Group 3 - The implementation of low-intensity monitoring led to a 30% reduction in ICU admission rates in U.S. hospitals, alleviating pressure on nursing resources [3] - The research team recommends incorporating the low-intensity monitoring protocol for low-risk patients into clinical guidelines to benefit more healthcare systems and patients [3] - Future research includes the establishment of a global research collaboration platform called "ACT-GLOBAL," aiming to enhance clinical trial efficiency by 40% and reduce research cycles by 30% [4]